TapewireFind a company

person · Reporting owner

O'Kane Kieran

Disclosed activity across 1 company

Tapewire entity
65172
SEC CIK
0001828131

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BIODESIX INCBDSX · Entity 6053Chief Commercial OfficerFebruary 20, 2026February 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIODESIX INC

Report date February 20, 2026 · Filed February 24, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect9,819 Ending reported balance After 2026-02-23 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-02-20 · Exercise / conversion · Acquired 1,469 · Balance 10,354

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Row 2 · 2026-02-23 · Sale · Disposed 535 · Balance 9,819

F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect4,406 Reported balance After 2026-02-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-02-20 · Exercise / conversion · Disposed 1,469 · Balance 4,406

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 08, 2024 Filed Feb 13, 2024 02:45 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 32,024 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-24-000585 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,736

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
November 10, 2023 Filed Nov 13, 2023 21:50 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 235 $1.23 $288.02
Disclosure

SEC source: 0000905148-23-001383 · form4.xml · nonDerivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,712

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 09, 2023 Filed Nov 13, 2023 21:50 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 234 $1.27 $297.34
Disclosure

SEC source: 0000905148-23-001383 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,947

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.23 to $1.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 21:50 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,489 $0.00 $0.00
Disclosure

SEC source: 0000905148-23-001383 · form4.xml · derivative · entry 4

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,405

Underlying: Common Stock · 1,489 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 21:50 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 1,489 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-23-001383 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,181

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
August 10, 2023 Filed Aug 10, 2023 23:28 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 849 $1.27 $1,075.60
Disclosure

SEC source: 0000905148-23-000666 · form4.xml · nonDerivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,692

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 09, 2023 Filed Aug 10, 2023 23:28 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 850 $1.39 $1,180.06
Disclosure

SEC source: 0000905148-23-000666 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,541

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 08, 2023 Filed Aug 10, 2023 23:28 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,972 $0.00 $0.00
Disclosure

SEC source: 0000905148-23-000666 · form4.xml · derivative · entry 5

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,972 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F6 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
August 08, 2023 Filed Aug 10, 2023 23:28 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,490 $0.00 $0.00
Disclosure

SEC source: 0000905148-23-000666 · form4.xml · derivative · entry 4

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,894

Underlying: Common Stock · 1,490 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
August 08, 2023 Filed Aug 10, 2023 23:28 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 5,462 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-23-000666 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,391

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
August 03, 2023 Filed Aug 7, 2023 21:31 UTC BIODESIX INC BDSX · Entity 6053 GrantCommon Stock 6,172 $1.62 $9,998.64
Disclosure

SEC source: 0000905148-23-000625 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,929

Read SEC document
July 24, 2023 Filed Jul 26, 2023 22:14 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 11,564 Not disclosed Strike: $1.20 Not disclosed
Disclosure

SEC source: 0000905148-23-000511 · form4.xml · derivative · entry 5

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,564

Underlying: Common Stock · 11,564 shares

Expires 2033-07-23

F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · kind: The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · price: The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F5 · derivative.exercise_date: This Replacement Option vests as follows: 8,864 shares of Common Stock underlying this Replacement Option vest on August 1, 2024, and the remaining 2,700 shares of Common Stock underlying this Replacement Option vest in 31 successive, equal monthly installments beginning on August 1, 2024.

Read SEC document
July 24, 2023 Filed Jul 26, 2023 22:14 UTC BIODESIX INC BDSX · Entity 6053 Disposition to issuerStock Options (Right to buy) · Derivative 31,055 Not disclosed Strike: $20.67 Not disclosed
Disclosure

SEC source: 0000905148-23-000511 · form4.xml · derivative · entry 4

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 31,055 shares

Expires 2031-02-22

F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · kind: The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · price: The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F2 · derivative.exercise_date: This option was fully vested as of the grant date.

Read SEC document
July 24, 2023 Filed Jul 26, 2023 22:14 UTC BIODESIX INC BDSX · Entity 6053 Disposition to issuerStock Options (Right to buy) · Derivative 25,599 Not disclosed Strike: $20.67 Not disclosed
Disclosure

SEC source: 0000905148-23-000511 · form4.xml · derivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,599 shares

Expires 2031-02-22

F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · kind: The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · price: The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F1 · derivative.exercise_date: This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021.

Read SEC document
May 10, 2023 Filed May 11, 2023 00:16 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 474 $1.58 $747.07
Disclosure

SEC source: 0001140361-23-023968 · form4.xml · nonDerivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,757

F3 · kind: These shares of the Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.5332 to $1.615, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 09, 2023 Filed May 11, 2023 00:16 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 1,223 $1.57 $1,915.71
Disclosure

SEC source: 0001140361-23-023968 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,231

F3 · kind: These shares of the Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs.

F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.53 to $1.6039, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 08, 2023 Filed May 11, 2023 00:16 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,972 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-023968 · form4.xml · derivative · entry 5

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,972

Underlying: Common Stock · 3,972 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.

F7 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F7 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
May 08, 2023 Filed May 11, 2023 00:16 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,489 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-023968 · form4.xml · derivative · entry 4

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,384

Underlying: Common Stock · 1,489 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F6 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
May 08, 2023 Filed May 11, 2023 00:16 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 5,461 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-23-023968 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,454

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 10,000 shares purchased under the Issuer's Employee Stock Purchase Plan on February 28, 2023.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:16 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 52,531 $0.00 Strike: $2.00 $0.00
Disclosure

SEC source: 0001140361-23-010024 · form4.xml · derivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,531

Underlying: Common Stock · 52,531 shares

Expires 2033-02-28

F1 · derivative.exercise_date: This option vested in full on March 1, 2023. Under the Issuer's 2022 Bonus-to-Options Program, the Reporting Person elected to receive a portion of the annual cash bonus earned during 2022 in the form of a fully-vested option.

Read SEC document
February 09, 2023 Filed Feb 10, 2023 23:40 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 1,999 $1.80 $3,596.40
Disclosure

SEC source: 0001140361-23-006073 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,993

F2 · kind: These shares of Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 08, 2023 Filed Feb 10, 2023 23:40 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,971 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-006073 · form4.xml · derivative · entry 5

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,944

Underlying: Common Stock · 3,971 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock.

F6 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F6 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 08, 2023 Filed Feb 10, 2023 23:40 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,490 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-006073 · form4.xml · derivative · entry 4

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,873

Underlying: Common Stock · 1,490 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock.

F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 08, 2023 Filed Feb 10, 2023 23:40 UTC BIODESIX INC BDSX · Entity 6053 GrantRestricted Stock Units · Derivative 122,135 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-006073 · form4.xml · derivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,135

Underlying: Common Stock · 122,135 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock.

F4 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F4 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 08, 2023 Filed Feb 10, 2023 23:40 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 5,461 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-23-006073 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,992

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock.

Read SEC document
November 21, 2022 Filed Nov 21, 2022 23:02 UTC BIODESIX INC BDSX · Entity 6053 GrantCommon Stock 4,347 $1.15 $4,999.05
Disclosure

SEC source: 0001140361-22-042598 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,531

Read SEC document
November 10, 2022 Filed Nov 11, 2022 02:02 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 753 $1.02 $766.18
Disclosure

SEC source: 0001140361-22-041082 · form4.xml · nonDerivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,184

F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs.

F6 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 09, 2022 Filed Nov 11, 2022 02:02 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 952 $1.04 $991.79
Disclosure

SEC source: 0001140361-22-041082 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,937

F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 08, 2022 Filed Nov 11, 2022 02:02 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,972 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-041082 · form4.xml · derivative · entry 5

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,915

Underlying: Common Stock · 3,972 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
November 08, 2022 Filed Nov 11, 2022 02:02 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,489 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-041082 · form4.xml · derivative · entry 4

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,363

Underlying: Common Stock · 1,489 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
November 08, 2022 Filed Nov 11, 2022 02:02 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 5,461 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-22-041082 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,889

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

Read SEC document
August 09, 2022 Filed Aug 10, 2022 22:53 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 1,673 $2.53 $4,229.68
Disclosure

SEC source: 0001140361-22-029133 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,428

F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $2.38 to $2.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 08, 2022 Filed Aug 10, 2022 22:53 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,972 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-029133 · form4.xml · derivative · entry 4

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,887

Underlying: Common Stock · 3,972 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
August 08, 2022 Filed Aug 10, 2022 22:53 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,490 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-029133 · form4.xml · derivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,852

Underlying: Common Stock · 1,490 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
August 08, 2022 Filed Aug 10, 2022 22:53 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 5,462 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-22-029133 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,101

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

Read SEC document
May 10, 2022 Filed May 12, 2022 01:42 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 1,583 $1.83 $2,896.89
Disclosure

SEC source: 0001140361-22-018736 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,639

F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 09, 2022 Filed May 12, 2022 01:42 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,972 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-018736 · form4.xml · derivative · entry 4

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,859

Underlying: Common Stock · 3,972 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
May 09, 2022 Filed May 12, 2022 01:42 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,489 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-018736 · form4.xml · derivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,342

Underlying: Common Stock · 1,489 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
May 09, 2022 Filed May 12, 2022 01:42 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 5,461 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-22-018736 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,222

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F6 · balance_after: Includes 1,157 and 2,604 Shares acquired under the BDSX stock purchase plan on August 31, 2021 and February 28, 2022, respectively.

Read SEC document
March 10, 2022 Filed Mar 14, 2022 21:51 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 6,162 $0.00 Strike: $2.29 $0.00
Disclosure

SEC source: 0001567619-22-006920 · doc1.xml · derivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,162

Underlying: Common Stock · 6,162 shares

Expires 2032-03-09

Read SEC document
March 10, 2022 Filed Mar 14, 2022 21:51 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 4,211 $0.00 Strike: $0.77 $0.00
Disclosure

SEC source: 0001567619-22-006920 · doc1.xml · derivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,423

Underlying: Common Stock · 4,211 shares

Expires 2030-04-14

F1 · shares: On April 15, 2020, the Reporting Person was granted an option to purchase 8,423 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years.

F3 · shares: On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 4,211 shares underlying the option.

F1 · derivative.exercise_date: On April 15, 2020, the Reporting Person was granted an option to purchase 8,423 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years.

F3 · derivative.exercise_date: On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 4,211 shares underlying the option.

Read SEC document
February 08, 2022 Filed Feb 11, 2022 00:09 UTC BIODESIX INC BDSX · Entity 6053 GrantRestricted Stock Units · Derivative 23,831 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-004588 · form4.xml · derivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,831

Underlying: Common Stock · 23,831 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 08, 2022 Filed Feb 11, 2022 00:09 UTC BIODESIX INC BDSX · Entity 6053 GrantRestricted Stock Units · Derivative 23,831 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-004588 · form4.xml · derivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,831

Underlying: Common Stock · 23,831 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 23, 2021 Filed Mar 14, 2022 21:51 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 4,212 $0.00 Strike: $0.77 $0.00
Disclosure

SEC source: 0001567619-22-006920 · doc1.xml · derivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,212

Underlying: Common Stock · 4,212 shares

Expires 2030-04-14

F1 · shares: On April 15, 2020, the Reporting Person was granted an option to purchase 8,423 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years.

F2 · shares: On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 4,212 shares underlying the option.

F1 · derivative.exercise_date: On April 15, 2020, the Reporting Person was granted an option to purchase 8,423 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years.

F2 · derivative.exercise_date: On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 4,212 shares underlying the option.

Read SEC document
February 23, 2021 Filed Jul 26, 2023 22:14 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 31,055 $0.00 Strike: $20.67 $0.00
Disclosure

SEC source: 0000905148-23-000511 · form4.xml · derivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,055

Underlying: Common Stock · 31,055 shares

Expires 2031-02-22

F2 · derivative.exercise_date: This option was fully vested as of the grant date.

Read SEC document
February 23, 2021 Filed Jul 26, 2023 22:14 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 25,599 $0.00 Strike: $20.67 $0.00
Disclosure

SEC source: 0000905148-23-000511 · form4.xml · derivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,599

Underlying: Common Stock · 25,599 shares

Expires 2031-02-22

F1 · derivative.exercise_date: This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.